#FORMAT=WebAnno TSV 3
#T_SP=de.tudarmstadt.ukp.dkpro.core.api.ner.type.NamedEntity|value


#Text=Blood samples from 125 unrelated families with classical type 2 neurofibromatosis (NF2) with bilateral vestibular schwannomas have been analysed for mutations in the NF2 gene. A further 17 families fulfilling modified criteria for NF2 have also been analysed. Causative mutations have been identified in 54 (43%) classical families and six (35%) of those fulfilling modified criteria. Forty-two cases from 38 families with truncating mutations had an average age at onset of symptoms of 19 years and diagnosis at 22.4 years. Fifty-one cases from 16 families with splice site mutations (15 from six), missense mutations (18 from six), and large deletions (18 from five) had an average age of onset of 27.8 years and at diagnosis of 33.4 years. Subjects with truncating mutations were significantly more likely to have symptoms before 20 years of age (p<0.001) and to develop at least two symptomatic CNS tumours in addition to vestibular schwannoma before 30 years (p<0.001). There were also significantly fewer multigenerational families with truncating mutations. Four further truncating mutations were in mosaic form and were associated with milder disease than other similar mutations. This large study has confirmed the previous impression that truncating mutations are associated with severe disease, but caution has to be exercised in using mutation type to predict disease course.
1-1	0-5	Blood	_
1-3	6-13	samples	_
1-5	14-18	from	_
1-7	19-22	125	_
1-9	23-32	unrelated	_
1-11	33-41	families	_
1-13	42-46	with	_
1-15	47-56	classical	_
1-17	57-61	type	_
1-19	62-63	2	_
1-21	64-81	neurofibromatosis	HPO[0]
1-23	82-83	(	_
1-24	83-86	NF2	_
1-25	86-87	)	_
1-27	88-92	with	_
1-29	93-102	bilateral	HPO[1]
1-31	103-113	vestibular	_
1-33	114-125	schwannomas	HPO[2]
1-35	126-130	have	_
1-37	131-135	been	_
1-39	136-144	analysed	_
1-41	145-148	for	_
1-43	149-158	mutations	_
1-45	159-161	in	_
1-47	162-165	the	_
1-49	166-169	NF2	_
1-51	170-174	gene	_
1-52	174-175	.	_
1-54	176-177	A	_
1-56	178-185	further	_
1-58	186-188	17	_
1-60	189-197	families	_
1-62	198-208	fulfilling	_
1-64	209-217	modified	_
1-66	218-226	criteria	_
1-68	227-230	for	_
1-70	231-234	NF2	_
1-72	235-239	have	_
1-74	240-244	also	_
1-76	245-249	been	_
1-78	250-258	analysed	_
1-79	258-259	.	_
1-81	260-269	Causative	_
1-83	270-279	mutations	_
1-85	280-284	have	_
1-87	285-289	been	_
1-89	290-300	identified	_
1-91	301-303	in	_
1-93	304-306	54	_
1-95	307-308	(	_
1-96	308-310	43	_
1-97	310-312	%)	_
1-99	313-322	classical	_
1-101	323-331	families	_
1-103	332-335	and	_
1-105	336-339	six	_
1-107	340-341	(	_
1-108	341-343	35	_
1-109	343-345	%)	_
1-111	346-348	of	_
1-113	349-354	those	_
1-115	355-365	fulfilling	_
1-117	366-374	modified	_
1-119	375-383	criteria	_
1-120	383-384	.	_
1-122	385-390	Forty	_
1-123	390-391	-	_
1-124	391-394	two	_
1-126	395-400	cases	_
1-128	401-405	from	_
1-130	406-408	38	_
1-132	409-417	families	_
1-134	418-422	with	_
1-136	423-433	truncating	_
1-138	434-443	mutations	_
1-140	444-447	had	_
1-142	448-450	an	_
1-144	451-458	average	_
1-146	459-462	age	_
1-148	463-465	at	_
1-150	466-471	onset	HPO[3]
1-152	472-474	of	_
1-154	475-483	symptoms	_
1-156	484-486	of	_
1-158	487-489	19	_
1-160	490-495	years	_
1-162	496-499	and	_
1-164	500-509	diagnosis	_
1-166	510-512	at	_
1-168	513-515	22	_
1-169	515-516	.	_
1-170	516-517	4	_
1-172	518-523	years	_
1-173	523-524	.	_
1-175	525-530	Fifty	_
1-176	530-531	-	_
1-177	531-534	one	_
1-179	535-540	cases	_
1-181	541-545	from	_
1-183	546-548	16	_
1-185	549-557	families	_
1-187	558-562	with	_
1-189	563-569	splice	_
1-191	570-574	site	_
1-193	575-584	mutations	_
1-195	585-586	(	_
1-196	586-588	15	_
1-198	589-593	from	_
1-200	594-597	six	_
1-201	597-599	),	_
1-203	600-608	missense	_
1-205	609-618	mutations	_
1-207	619-620	(	_
1-208	620-622	18	_
1-210	623-627	from	_
1-212	628-631	six	_
1-213	631-633	),	_
1-215	634-637	and	_
1-217	638-643	large	_
1-219	644-653	deletions	_
1-221	654-655	(	_
1-222	655-657	18	_
1-224	658-662	from	_
1-226	663-667	five	_
1-227	667-668	)	_
1-229	669-672	had	_
1-231	673-675	an	_
1-233	676-683	average	_
1-235	684-687	age	_
1-237	688-690	of	_
1-239	691-696	onset	HPO[4]
1-241	697-699	of	_
1-243	700-702	27	_
1-244	702-703	.	_
1-245	703-704	8	_
1-247	705-710	years	_
1-249	711-714	and	_
1-251	715-717	at	_
1-253	718-727	diagnosis	_
1-255	728-730	of	_
1-257	731-733	33	_
1-258	733-734	.	_
1-259	734-735	4	_
1-261	736-741	years	_
1-262	741-742	.	_
1-264	743-751	Subjects	_
1-266	752-756	with	_
1-268	757-767	truncating	_
1-270	768-777	mutations	_
1-272	778-782	were	_
1-274	783-796	significantly	_
1-276	797-801	more	_
1-278	802-808	likely	_
1-280	809-811	to	_
1-282	812-816	have	_
1-284	817-825	symptoms	_
1-286	826-832	before	_
1-288	833-835	20	_
1-290	836-841	years	_
1-292	842-844	of	_
1-294	845-848	age	_
1-296	849-850	(	_
1-297	850-851	p	_
1-298	851-852	<	_
1-299	852-853	0	_
1-300	853-854	.	_
1-301	854-857	001	_
1-302	857-858	)	_
1-304	859-862	and	_
1-306	863-865	to	_
1-308	866-873	develop	_
1-310	874-876	at	_
1-312	877-882	least	_
1-314	883-886	two	_
1-316	887-898	symptomatic	_
1-318	899-902	CNS	_
1-320	903-910	tumours	_
1-322	911-913	in	_
1-324	914-922	addition	_
1-326	923-925	to	_
1-328	926-936	vestibular	HPO[5]
1-330	937-947	schwannoma	HPO[5]|HPO[6]
1-332	948-954	before	_
1-334	955-957	30	_
1-336	958-963	years	_
1-338	964-965	(	_
1-339	965-966	p	_
1-340	966-967	<	_
1-341	967-968	0	_
1-342	968-969	.	_
1-343	969-972	001	_
1-344	972-974	).	_
1-346	975-980	There	_
1-348	981-985	were	_
1-350	986-990	also	_
1-352	991-1004	significantly	_
1-354	1005-1010	fewer	_
1-356	1011-1028	multigenerational	_
1-358	1029-1037	families	_
1-360	1038-1042	with	_
1-362	1043-1053	truncating	_
1-364	1054-1063	mutations	_
1-365	1063-1064	.	_
1-367	1065-1069	Four	_
1-369	1070-1077	further	_
1-371	1078-1088	truncating	_
1-373	1089-1098	mutations	_
1-375	1099-1103	were	_
1-377	1104-1106	in	_
1-379	1107-1113	mosaic	_
1-381	1114-1118	form	_
1-383	1119-1122	and	_
1-385	1123-1127	were	_
1-387	1128-1138	associated	_
1-389	1139-1143	with	_
1-391	1144-1150	milder	_
1-393	1151-1158	disease	_
1-395	1159-1163	than	_
1-397	1164-1169	other	_
1-399	1170-1177	similar	_
1-401	1178-1187	mutations	_
1-402	1187-1188	.	_
1-404	1189-1193	This	_
1-406	1194-1199	large	_
1-408	1200-1205	study	_
1-410	1206-1209	has	_
1-412	1210-1219	confirmed	_
1-414	1220-1223	the	_
1-416	1224-1232	previous	_
1-418	1233-1243	impression	_
1-420	1244-1248	that	_
1-422	1249-1259	truncating	_
1-424	1260-1269	mutations	_
1-426	1270-1273	are	_
1-428	1274-1284	associated	_
1-430	1285-1289	with	_
1-432	1290-1296	severe	HPO[7]
1-434	1297-1304	disease	_
1-435	1304-1305	,	_
1-437	1306-1309	but	_
1-439	1310-1317	caution	_
1-441	1318-1321	has	_
1-443	1322-1324	to	_
1-445	1325-1327	be	_
1-447	1328-1337	exercised	_
1-449	1338-1340	in	_
1-451	1341-1346	using	_
1-453	1347-1355	mutation	_
1-455	1356-1360	type	_
1-457	1361-1363	to	_
1-459	1364-1371	predict	_
1-461	1372-1379	disease	_
1-463	1380-1386	course	_
1-464	1386-1387	.	_
